Stifel Nicolaus Cuts Black Diamond Therapeutics (NASDAQ:BDTX) Price Target to $15.00

Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) had its price objective decreased by equities research analysts at Stifel Nicolaus from $16.00 to $15.00 in a report released on Friday,Benzinga reports. The firm presently has a "buy" rating on the stock.

Separately, Wedbush reaffirmed an "outperform" rating and issued a $11.00 price target (down previously from $16.00) on shares of Black Diamond Therapeutics in a research report on Friday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $14.40.

Black Diamond Therapeutics Stock Down 1.2 %

Shares of NASDAQ BDTX traded down $0.02 on Friday, reaching $1.69. 508,177 shares of the company's stock traded hands, compared to its average volume of 816,156. The business's 50 day simple moving average is $2.22 and its two-hundred day simple moving average is $3.10. Black Diamond Therapeutics has a 12 month low of $1.59 and a 12 month high of $7.66. The company has a market cap of $95.63 million, a price-to-earnings ratio of -1.27 and a beta of 2.52.

Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) last posted its quarterly earnings data on Thursday, March 6th. The company reported ($0.28) earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.03. Analysts forecast that Black Diamond Therapeutics will post -1.3 earnings per share for the current fiscal year.

Remove Ads

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of BDTX. D. E. Shaw & Co. Inc. bought a new stake in Black Diamond Therapeutics in the 4th quarter worth about $37,000. Intech Investment Management LLC grew its stake in shares of Black Diamond Therapeutics by 49.1% in the fourth quarter. Intech Investment Management LLC now owns 19,247 shares of the company's stock worth $41,000 after acquiring an additional 6,340 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Black Diamond Therapeutics by 429.6% during the fourth quarter. JPMorgan Chase & Co. now owns 18,929 shares of the company's stock valued at $41,000 after purchasing an additional 15,355 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Black Diamond Therapeutics during the fourth quarter valued at approximately $42,000. Finally, Wells Fargo & Company MN lifted its position in Black Diamond Therapeutics by 41.8% during the fourth quarter. Wells Fargo & Company MN now owns 20,119 shares of the company's stock valued at $43,000 after purchasing an additional 5,932 shares during the period. 95.47% of the stock is owned by institutional investors.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.